A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty
Latest Information Update: 24 Dec 2024
At a glance
- Drugs REGN 9933 (Primary) ; Apixaban; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms ROXI-VTE I
- Sponsors Regeneron Pharmaceuticals
- 19 Dec 2024 Results presented in a Regeneron Pharmaceuticals Media Release.
- 04 Jun 2024 Status changed from active, no longer recruiting to completed.
- 26 Mar 2024 Planned End Date changed from 10 Aug 2024 to 29 May 2024.